QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.

This study evaluated the efficacy of olanzapine in preventing chemotherapy-induced nausea and vomiting (CINV) and improving the quality of life (QoL) of patients with cancer during chemotherapy. Two hundred twenty-nine patients with cancer who received chemotherapy from January 2008 to August 2008 were enrolled, and they were randomised to receive olanzapine or a 5-HT3 receptor antagonist. The patients completed a CINV questionnaire once daily on days 1-5 and a QoL questionnaire on days 0 and 6. The complete response (CR) rates for nausea (76.85% versus 46.2%) and vomiting (84.3% versus 67.6%) were significantly higher in the olanzapine group than in the 5-HT3 receptor antagonist group for delayed CINV but not for acute CINV. The CR rates for nausea (76.85% versus 44.44%) and vomiting (85.95% versus 67.59%) were also significantly higher in the olanzapine group for the 5 days post-chemotherapy. After chemotherapy, global health status, emotional functioning, and insomnia were improved in the olanzapine group but worsened in the 5-HT3 receptor antagonist group, whereas cognitive functioning and appetite loss were unchanged. Moreover, olanzapine significantly improved global health status, emotional functioning, social functioning, fatigue, nausea/vomiting, insomnia, and appetite loss. Olanzapine improved the QoL of patients with cancer during chemotherapy, in part by reducing the incidence of delayed CINV.

[1]  G. Nocea,et al.  Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life , 2012, Supportive Care in Cancer.

[2]  O. Clark,et al.  Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis , 2011, Supportive Care in Cancer.

[3]  M. Tonato,et al.  Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) , 2011, Supportive Care in Cancer.

[4]  E. Rubenstein,et al.  Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. , 2010, European journal of pharmacology.

[5]  Xiuli Liu,et al.  Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting , 2009, Journal of experimental & clinical cancer research : CR.

[6]  T. Perrone,et al.  Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy , 2009, Supportive Care in Cancer.

[7]  E. Ming,et al.  Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings , 2007, Supportive Care in Cancer.

[8]  Cynthia S. Johnson,et al.  A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study , 2007, Supportive Care in Cancer.

[9]  Panagiotis Mavros,et al.  Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Kris,et al.  Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy , 2005, Supportive Care in Cancer.

[12]  H. Eichler,et al.  Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Osoba,et al.  Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update , 2005, Supportive Care in Cancer.

[14]  Sin-Ho Jung,et al.  A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study , 2004, Cancer investigation.

[15]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[17]  Mellar P. Davis,et al.  Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. , 2003, Journal of pain and symptom management.

[18]  S. Passik,et al.  A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. , 2003, Journal of pain and symptom management.

[19]  S. Passik,et al.  A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. , 2002, Journal of pain and symptom management.

[20]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[21]  N. Pavlidis,et al.  A Randomized Open-Label Parallel-Group Study Comparing Ondansetron with Ondansetron plus Dexamethasone in Patients with Metastatic Breast Cancer Receiving High-Dose Epirubicin. A Hellenic Cooperative Oncology Group Study , 2000, Tumori.

[22]  T. Stern,et al.  New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. , 1999, Psychosomatics.

[23]  C. García-Girón,et al.  Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. , 1998, Anti-cancer drugs.

[24]  D. Osoba,et al.  The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy , 1998, Supportive Care in Cancer.

[25]  M. Marty,et al.  Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group. , 1994, British Journal of Cancer.

[26]  G. Giaccone,et al.  Antiemetic Activity of Oral Lorazepam in Addition to Methylprednisolone and Metoclopramide in the Prophylactic Treatment of Vomiting Induced by Cisplatin. A Double-Blind, Placebo-Controlled Study with Crossover Design , 1993, Tumori.

[27]  A. Villalon,et al.  Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis , 2004, Supportive Care in Cancer.

[28]  B. Glimelius,et al.  Assessment of quality of life during chemotherapy. , 2001, Acta oncologica.

[29]  D. Khayat,et al.  A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting , 2000, Supportive Care in Cancer.

[30]  V. Moreno,et al.  Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. , 1998, European journal of cancer.

[31]  J. Feliu,et al.  Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam. , 1991, Acta oncologica.